References
- AjaniJReview of capecitabine as oral treatment of gastric, gastroesophageal, and esophageal cancersCancer20061072213116770784
- AjaniJAFaustJIkedaKPhase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinomaJ Clin Oncol20052369576516145066
- AjaniJALeeFCSinghDAMulticenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinomaJ Clin Oncol200624663716446338
- CamidgeRReignerBCassidyJSignificant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancerJ Clin Oncol20052347192516034047
- Cancer Facts and Figures2006 [online]. Accessed March 28, 2007. URL: http://www.cancer.org
- CholletPSchoffskiPWeigang-KohlerKPhase II trial of S-1 in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)Eur J Cancer20033912647012763215
- CunninghamDRaoSStarlingNRandomized multicenter phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced esophagogastric cancer. The REAL 2 trialProc Am Soc Clin Oncol20062418S Abstract no. LBA4017
- DankMZaluskiJBaroneCRandomized phase 3 trial of irinotecan (CPT-11) 5FU/folinic acid (FA) vs CDDP 5FU in 1st-line advanced gastric cancer patientsProc Am Soc Clin Oncol Gastrointestinal Cancers Symposium, 20052005 Abstract 61
- DhillonSScottLJCapecitabine: in advanced gastric or gastroesophageal cancerDrugs2007676011017352519
- HongYSSongSYLeeSIA phase II trial of capecitabine in previously untreated patients with advanced and/or metastatic gastric cancerAnn Oncol2004151344715319239
- KangYKangWKShinDBRandomized phase III trial of capecitabine/cisplatin (XP) vs. continuous infusion of 5-FU/cisplatin (FP) as first-line therapy in patients with advanced gastric cancer: efficacy and safety resultsProc Am Soc Clin Oncol20062418S Abstract no. LBA 4018
- KochiMFujiiMKanamoriNEffect of gastrectomy on the pharmacokinetics of S-1, an oral fluoropyrimidine, in resectable gastric cancer patientsCancer Chemother Pharmacol20076069370117690883
- KoizumiWSaigenjiKUjiieSA pilot phase II study of capecitabine in advanced or recurrent gastric cancerOncology200364232612697963
- KondoKChinKSakamotoJA multicenter phase II trial using 4-week cycles of capecitabine in advanced/metastatic gastric cancer (AGC)Proc Am Soc Clin Oncol200322321 Abstract 1289
- LenzH-JLeeF-CHallerDGExtended safety and efficacy data on S-1 plus cisplatin in patients with untreated advanced gastric carcinoma in a multi-center phase II studyCancer2007109334017133415
- LouvetCAndreTTigaudJPhase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patientsJ Clin Oncol2002204543812454110
- PohlHWelchHGThe role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidenceJ Natl Cancer Inst200597142615657344
- Roche Laboratories IncXeloda (capecitabine) tablets prescribing information. [online]2005 Accessed September 15, 2005. URL: http://www. rocheusa.com/products/xeloda/pipdf
- SakamotoJChinKKondoKPhase II study of a 4-week capecitabine regimen in advanced or recurrent gastric cancerAnticancer Drugs200617231616428943
- SchullerJCassidyJDumontEPreferential activation of capecitabine in tumor following oral administration to colorectal cancer patientsCancer Chemother Pharmacol200045291710755317
- Van CutsemEMoiseyenkoVMTjulandinSPhase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study GroupJ Clin Oncol2006244991717075117